Skip to main content
Toggle navigation
Login
Search
Home
Browse by Poster Title
Home
Browse by Poster Title
Browse by Poster Title
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#
Sort by
#
Sort by
Title
8
T-045
89Zr-mAb uptake interpretation requires the use of tissue to plasma ratios corrected for antibody catabolism
Favorite
A
S-114
A Bayesian Population Pharmacokinetic Analysis of Oritavancin in Pediatric Patients with Skin Infections
Favorite
M-044
A Case Study Showcasing the Impact of the InSilicoTrials Platform on Obesity Clinical Trials
Favorite
M-114
A Dose That Fits All: Model-Based Insights into the Impact of Obesity on Midazolam Oromucosal Pharmacokinetics in Adults
Favorite
T-103
A Fisher Information Matrix-based Analysis to Determine Precision of Estimated PK Parameters for Reduced Sample Sizes in Pediatric Studies in Rare Diseases
Favorite
T-089
A Framework for Developing a Virtual Murine Cohort: Applications to Adoptive Cell Therapy in Bladder Cancer
Favorite
S-095
A Julia Package for Traceable and Reproducible Models in Quantitative Systems Pharmacology
Favorite
T-088
A Mechanistic Pharmacokinetic/Pharmacodynamic Model for CD19 Targeting Therapies for Autoimmune Diseases
Favorite
T-050
A Mechanistic Pharmacokinetic-Pharmacodynamic Model Framework for Degrader-Antibody Conjugates
Favorite
T-028
A Mechanistic Pharmacokinetics and Pharmacodynamics (PK/PD) Platform Model for Induced proximity-based therapeutics - PROTACs
Favorite
M-101
A minimal model to support a CAR T-cell therapy development platform
Favorite
S-012
A Minimal-Quantitative Systems Pharmacology Model for Dual-Targeting Bispecific T Cell Modulators in Immuno-Oncology for Solid Tumors
Favorite
T-057
A Model Based Meta Analysis of Ulcerative Colitis for Clinical Remission
Favorite
T-057
A Model Based Meta Analysis of Ulcerative Colitis for Clinical Remission
Favorite
T-029
A Model-Based Meta-Analysis Framework to Predict and Manage ADC-Related Grade 3+ Neutropenia Across Clinical Studies
Favorite
M-022
A multi-model strategy in R to address cytopenia
Favorite
T-109
A Multi-route, Multi-formulation Population Pharmacokinetic Framework for THC and 11-OH-THC Reflecting Real-World Use
Favorite
S-009
A novel approach for predicting the efficacy of updated vaccines when the correlate of protection is known
Favorite
S-116
A Novel Bayesian Adaptive Design for Phase I Dose Escalation with Improved Efficiency and Accuracy in Estimation of Maximum Tolerated Dose
Favorite
M-082
A Novel Estimation Method for a Globally Unidentifiable Linear Compartment Models Using Bayesian Constraint Relaxation
Favorite
M-082
A Novel Estimation Method for a Globally Unidentifiable Linear Compartment Models Using Bayesian Constraint Relaxation
Favorite
T-056
A novel mechanistic mathematical model of liver transplant immune dynamics predicts important drivers of patient outcome
Favorite
S-025
A Novel Multi-Agent Framework for Automated Pharmacometric Analysis with Human-Like Reasoning
Favorite
S-088
A pediatric PBPK model of atropine gel to predict atropine levels in children with neurological disorders after administration to oral cavity
Favorite
M-028
A Pharmacometrics Strategy for Ensuring Compatibility of Exposure-Response Analysis with Clinical Study Report: Enhancing Accuracy, Traceability, and Transferability Through Variable Mapping Specification (VMS)
Favorite
M-039
A Physiologically Based Pharmacokinetic Framework for Predicting Drug Exposure in the Female Reproductive Tract
Favorite
S-038
A Physiologically Based Pharmacokinetic Model of Ceftriaxone in Healthy Adults and Pregnant Women
Favorite
T-015
A pipeline for generating large virtual dog populations to predict preclinical drug-induced liver injury
Favorite
T-073
A PK/PD Model to Evaluate Uricosuric Clinical Efficacy versus Therapeutic Window for Treatment of Gout
Favorite
S-101
A Population Pharmacokinetic Approach to Prospectively Assess Vancomycin Pharmacokinetics in Adult Jordanian Patients: a Step towards Personalized Dosing
Favorite
T-081
A Population PK Approach to Evaluate Plasma and ELF Exposure Changes Following Co-administration of Spectinamide 1599 and Pyrazinamide in Mice
Favorite
M-024
A Population PK-PD Model-Informed Approach to Guide Formulation Development
Favorite
S-087
A Quantitative Systems Pharmacology (QSP) Model Platform to Study the Impact of Intra-tumoral Heterogeneity on Antibody-Drug Conjugate (ADC) Treatment Efficacy
Favorite
M-037
A quantitative systems pharmacology model of felzartamab, an anti-CD38 antibody, to link immune cell and pharmacodynamic responses in immune mediated diseases
Favorite
T-024
A Scalable, Traceable and Integrated Tool for Large QSP Models Calibration
Favorite
T-061
A semi-mechanistic PKPD model of CSL112 harmonizes the differential cholesterol efflux capacities (CEC) of high-density lipoprotein across different dose groups
Favorite
S-041
A simulation-based Comparison of Approaches to Safety Outcome Estimation in Special Populations
Favorite
S-078
A Translational QSP Modeling Framework Demonstrates Tissue-Level Pharmacokinetics Do Not Predict the Clinical Efficacy of FTC/TDF PrEP
Favorite
S-063
A Translational Quantitative Systems Pharmacology Framework For Alpha-Synuclein-Targeted Parkinson’s Therapies Integrating Pharmacokinetics, Neuronal Biophysics, And Pathological Network Oscillations
Favorite
S-063
A Translational Quantitative Systems Pharmacology Framework For Alpha-Synuclein-Targeted Parkinson’s Therapies Integrating Pharmacokinetics, Neuronal Biophysics, And Pathological Network Oscillations
Favorite
M-097
Accounting for Temporal Differences in Fetal Exposure during Pregnancy using Masking
Favorite
T-011
Accurate modeling of ACTH and cortisol dynamics for Cushing’s disease treatment
Favorite
T-014
ACS-SIMULATOR: A Shiny Application for Guiding Antenatal Corticosteroid Administration in Pregnant Women
Favorite
T-013
Adaptable PBPK-QSP gene therapy model applied to i.v. administration of AAV-2 across different species
Favorite
T-093
Adjusted Ideal Body Weight Dosing Reduces Pharmacokinetic Variability of the PD-L1 Targeted Antibody-Drug Conjugate PDL1V (PF-08046054)
Favorite
T-093
Adjusted Ideal Body Weight Dosing Reduces Pharmacokinetic Variability of the PD-L1 Targeted Antibody-Drug Conjugate PDL1V (PF-08046054)
Favorite
S-005
Amivantamab population pharmacokinetics analyses of PALOMA studies supporting the bridging from intravenous formulation to subcutaneous formulation in epidermal growth factor receptor-mutated non-small cell lung cancer
Favorite
S-070
Amplified Bioanalytical Uncertainty Propagation Impact on Population Pharmacokinetic Modeling
Favorite
S-090
An Empirical Drug Autoinduction Model to Characterize the Population Pharmacokinetics of TEV-56286 (Emrusolmin) in Healthy Participants and Patients
Favorite
T-041
An extended Bayesian semi-mechanistic dose-finding design in oncology using pharmacokinetic and pharmacodynamic information
Favorite
M-085
An innovative framework to find potential immunotherapy targets using QSP modeling and RNA-seq data
Favorite
M-106
An Integrated model of Lu-PSMA-617 dose, tumor dosimetry, PSA and OS to enable future study design
Favorite
M-087
An Integrated PK-PD Model to Characterize Circadian-Driven ACTH-Cortisol Interactions in Patients with Congenital Adrenal Hyperplasia
Favorite
M-016
Application of in silico Healthy Control Cohorts in the Analysis of Osivelotor Exposure in Organ Impairment
Favorite
T-052
Application of Neural ODEs for Agnostic Inference of Feedback Mechanism Structure in QSP Models
Favorite
T-019
Application of NSGA-II and pyDarwin in Multi-objective Optimization for Population Pharmacokinetic (PopPK) Model Selection
Favorite
S-019
Applying Mechanistic PKPD Models to Differentiate Inhibitors of Werner Syndrome Helicase Based on Predicted in vivo Target Engagement
Favorite
M-020
Assessment of Drug-Drug Interaction Effect of Gastric Acid Reducing Agents on Lazertinib Exposure in EGFR-Mutated Non-Small Cell Lung Cancer
Favorite
S-071
Assessment of Virtual Control Groups for Organ Impairment Studies Using Population Pharmacokinetic Simulation: Twin Matching versus Group Matching
Favorite
S-046
Assessment of Weight Loss by Amylin Receptor Agonists Alone and In Combination with GLP-1 Receptor Agonists: A Model-Based Meta-Analysis
Favorite
M-091
Auto-Induction and PD-Enhanced TMDD population PK Models for Engineered IL-15 cytokine Efbalropendekin alfa (XmAb24306) in Cancer Therapy
Favorite
S-072
Automated concentration-QT data preparation, model selection and reporting in R
Favorite
S-030
Automated Generation of Computational Models from Scientific Publications Using AI
Favorite
M-060
Automated Model Generation with Delineate Co-Pilot
Favorite
S-073
Automated simulation with parameter uncertainty from R with NONMEM and NMsim_NWPRI
Favorite
B
M-029
Bayesian Analysis of Nonclinical Studies to Inform Regimen Selection for Tuberculosis
Favorite
S-010
Bayesian modeling allows early inference of pharmacokinetic/pharmacodynamic relationship for a novel small molecule STING agonist in Phase I
Favorite
T-005
Bench to bedside modelling of mRNA encoding IgG using a multiscale mechanistic PK-PD model: A case study with anti-claudin 18.2
Favorite
T-009
Bridging Preclinical Data and Human Dose Selection for ADCs: Lessons from Approved Molecules
Favorite
C
S-031
Case Study: Integrating ADPPK CDISC Standards into Pharmacometric Programming and Analysis Workflows
Favorite
M-099
Case Study: Parameter Estimation of an NLME-QSP Model
Favorite
M-113
Characterization of PK Characteristics of IMMUNORHO after Intramuscular Administration for the Prevention of RhD Isoimmunisation in Rh(D) Negative Women Pregnant with Rh(D) Positive Fetuses: Population Pharmacokinetic Approach
Favorite
T-105
Characterizing Chimeric Aducanumab Disposition in a Preclinical Alzheimer’s Model Using Population PK Modeling
Favorite
T-059
Characterizing the Exposure–Response Relationship of MK-2060 in Participants with End Stage Kidney Disease Receiving Hemodialysis
Favorite
M-003
Characterizing the pharmacokinetics of MAM01, an extended half-life monoclonal antibody for the prevention of malaria using a population approach
Favorite
S-106
Clinical PK characterization of EGT710, a novel coronavirus Mpro inhibitor, and simulation of target attainment rates for efficacious dose prediction
Favorite
T-060
Clinical Utility Index Leveraging Results From Clinical Trial Simulation for Safety and Efficacy Outcomes Derived From Longitudinal Models
Favorite
M-078
Combining Mechanistic Modeling and Deep Learning for Predicting Survival Probabilities in Oncology
Favorite
M-017
Comparative Sensitivity Analysis of Semi-mechanistic and QSP Models of Humoral Response Following Vaccination
Favorite
M-104
Comparison of $PRED and $DES in NONMEM for time-varying categorical covariates in disease progression modeling.
Favorite
T-020
Comparison of Machine Learning and traditional Population Pharmacokinetic of Gabapentin in Neuropathic Pain
Favorite
T-077
Comparison of Population Pharmacokinetic Platforms, Monolix and Phoenix for Cephalexin in Infants
Favorite
T-101
Comparison of Predictive Performance of Complex IS/ID and Simple KPD Models on durability projections of Neutralizing Antibodies of LNP-mRNA-Based Vaccines
Favorite
S-054
Computer Modeling of Bevacizumab Drug Distribution After Intravitreal Injection in Rabbit and Human Eyes
Favorite
T-002
Concentration-QTc modeling for ponsegromab using pooled data from 3 phase 1 studies in healthy participants
Favorite
S-058
Concentration-QTcF Analysis Indicates Casdatifan Does Not Prolong QTcF
Favorite
T-018
Constrained Multi-Objective optimization population PK model selection in NLME and RDarwin.
Favorite
M-018
Construction of a Whole-Body Physiologically Based Pharmacokinetic (PBPK) Model to Facilitate the Design of LNP based mRNA Therapeutics for Secreted Protein Targets with Applications to Anti-Viral Therapies
Favorite
T-004
Continuous infusion simulations in PBPK and QSP models reveal steady-state properties and rate-limiting steps.
Favorite
D
T-106
DDIapp - A web-based application for static drug-drug interaction risk assessment.
Favorite
S-023
Deep Learning-Based Autoencoder for Outlier Detection in Dosing and Concentration-Time Data: Enabling Reliable Population Pharmacokinetic Modeling
Favorite
M-079
Deriving allometric scaling rules and providing Insights into the dynamics of LNP based mRNA therapeutics with an exactly solvable mathematical model
Favorite
M-105
Designing Optimal Pharmacokinetic Sampling Strategies for Ketamine in Established Status Epilepticus: A Model-Based Simulation Study to Support the Ketamine Add-On Therapy for Established Status Epilepticus Treatment Trial
Favorite
S-092
Developing a translational framework to predict clinical weight loss for novel or combination incretin therapies
Favorite
M-112
Development and Evaluation of PKPD Models for QT Interval Changes Post-Moxifloxacin Dosing in Non-Human Primates
Favorite
T-070
Development and External Validation of a Machine Learning Model to Predict Clearance in Patients with Epilepsy and Migraine Receiving Intravenous Topiramate with or without Enzyme-Inducing Comedications
Favorite
T-090
Development and validation of a model-based framework to inform the preclinical to clinical translation of Mpro inhibitor antivirals
Favorite
T-097
Development of a Combined Deposition–Physiologically Based Pharmacokinetic Model for Inhaled Treprostinil in Idiopathic Pulmonary Fibrosis
Favorite
S-021
Development of a Physiologically Based Infection Kinetic Model to Assess Bacterial Clearance by Various Immunocompromised Mouse Strains Used as Infection Models for Mycobacterium abscessus
Favorite
T-064
Development of a QSP model for the prediction of mRNA influenza vaccine immunogenicity
Favorite
T-064
Development of a QSP model for the prediction of mRNA influenza vaccine immunogenicity
Favorite
S-094
Development of a Quantitative Systems Pharmacology (QSP) Model of the Complement System Capturing Crosstalk Between the Classical and Alternative Pathways
Favorite
S-062
Development of a Quantitative Systems Pharmacology Model for Hepatitis B Virus Infection and Hepatitis D Virus Co-Infection.
Favorite
M-100
Development of a Quantitative Systems Toxicology Model to Predict Drug-Induced Liver Injury in Pediatrics
Favorite
M-100
Development of a Quantitative Systems Toxicology Model to Predict Drug-Induced Liver Injury in Pediatrics
Favorite
T-007
Development of a Unified QSP Framework to Characterize the Pharmacokinetics of TCBs
Favorite
T-047
Development of Dosing Selection Strategy for Brain Penetrants
Favorite
S-044
Development of nmbench: A Lightweight NONMEM Workbench extension for Efficient Population Modeling and Simulation
Favorite
T-040
Disease progression model for TKV and eGFR prediction in patients with autosomal dominant polycystic kidney disease
Favorite
M-083
Disease progression simulation via generative AI: assessing the credibility of a conditional longitudinal autoencoder via a case study in Alzheimer’s Disease
Favorite
M-115
Dosage modifications in exposure-response analyses of oncology drug development: the brigimadlin case study
Favorite
M-071
Dose optimization framework to estimate benefit-risk for oncology compounds: an integrated population model framework incorporating PK, safety, efficacy and impact of dose modifications
Favorite
S-022
Dose Optimization of Inhaled Tigecycline in Humans to Overcome Inherent Adverse Events and Maximize Bacterial Clearance Using a PBPK Modeling Approach
Favorite
T-027
Drug-drug interactions while breastfeeding with mother/infant medications: What's safe?
Favorite
E
T-112
Early sampling improves voriconazole target attainment in pediatric patients dosed with model-informed precision dosing tools: a simulation study
Favorite
S-001
Easy model creation using nlmixr2shiny and nlmixr2lib
Favorite
T-051
Efficient Generation of Plausible Virtual Populations Using Machine Learning Surrogate Classification Models
Favorite
T-096
Enabling Earlier Predictions of Hepatotoxic Risk with Quantitative Structure-Activity Relationship-Machine Learning (QSAR-ML) and Quantitative Systems Toxicology (QST) Models
Favorite
M-026
Enhancing Clinical Trial Simulations with Advanced Computational Techniques and Scalable Cloud Solutions
Favorite
M-025
Enhancing Model Interoperability and Workflow Integration in Clinical Trial Simulations
Favorite
S-018
Evaluating antibody drug conjugate (ADC) combinations using the platform Quantitative Systems Pharmacology (QSP) model
Favorite
M-046
Evaluating the feasibility of virtual controls in organ impairment studies using modeling and simulation
Favorite
M-098
Evaluating the impact of pharmacogenomic variants on aromatase inhibitor-induced bone toxicity using a quantitative systems pharmacology model of bone remodeling
Favorite
M-098
Evaluating the impact of pharmacogenomic variants on aromatase inhibitor-induced bone toxicity using a quantitative systems pharmacology model of bone remodeling
Favorite
S-069
Evaluation and Mitigation of Time-Dependent Confounding Effects in Conventional Exposure-Response Analyses for Small-Molecule Oncology Drugs
Favorite
M-038
Evaluation of Azithromycin Disposition in Pregnant Women Undergoing Cesarean Delivery – A Population-Based PBPK Modeling Approach
Favorite
S-026
Evaluation of Fluctuating Drug Concentration and Pharmacokinetic Effects on Time-to-event Endpoint Using Proportional Hazard Cox Regression in NONMEM
Favorite
T-012
Evaluation of Parallel Tempering for Efficient Generation of Virtual Populations
Favorite
M-053
Exploratory population pharmacokinetic analysis of vixarelimab using a two-target quasi-steady-state TMDD model in healthy volunteers and patients with pruritic conditions
Favorite
S-032
Exploring Python to Prepare CDISC-Compliant Analysis Datasets for Pharmacometric Analyses
Favorite
S-075
Exposure-Overall Survival Analysis for Quizartinib in Newly Diagnosed Patients with FLT3-Internal-Tandem-Duplication-Positive Acute Myeloid Leukemia
Favorite
M-073
Exposure-Response Analyses for Monthly Buprenorphine Extended-Release (BUP-XR) in Patients with Opioid Use Disorder and Frequent Fentanyl Use
Favorite
S-048
Exposure-Response Analyses of Dato-DXd in patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer
Favorite
T-087
Exposure-Response Analysis of Bleeding Events Following Weekly SC Flat Dose Marstacimab Administration in Hemophilia Participants Using Regression Modeling and Repeated-Time-To-Event (RTTE) Analyses
Favorite
T-100
Exposure-Response Analysis of Datopotamab Deruxtecan (Dato-DXd) in Combination with Pembrolizumab with or without Platinum Chemotherapy in Patients with Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
Favorite
M-008
Exposure-Response Analysis of Efficacy and Safety for Nivolumab + Relatlimab Fixed-dose Combination (FDC) to Support Dose Justification in Patients with Unresectable or Metastatic Melanoma
Favorite
T-083
Exposure-Response Analysis of Guselkumab in Induction Studies in Adults with Moderately to Severely Active Ulcerative Colitis in the QUASAR Program
Favorite
T-083
Exposure-Response Analysis of Guselkumab in Induction Studies in Adults with Moderately to Severely Active Ulcerative Colitis in the QUASAR Program
Favorite
M-052
Exposure-Response Analysis of Guselkumab in Participants with Moderate to Severe Crohn’s Disease
Favorite
T-062
Exposure-Response Analysis of Guselkumab in the Maintenance Phase in Adults with Moderately to Severely Active Ulcerative Colitis
Favorite
M-031
Exposure-Response Analysis of Seladelpar in Patients With Primary Biliary Cholangitis
Favorite
S-004
Exposure-Response Analysis of Ziftomenib in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Favorite
S-076
Exposure-Response Characterization of the Safety Profile for a Novel KAT6 Inhibitor, PF-07248144, For Use In Dose Optimization During a Phase 1 First-in-Patient Study
Favorite
T-078
Exposure-Response Modeling of Efficacy and Safety Endpoints of Sarilumab in Pediatric Patients with Polyarticular-Course Juvenile Arthritis
Favorite
M-111
Exposure-Response Relationship Between Litifilimab and Clinical Outcomes in Systemic Lupus Erythematosus Populations
Favorite
F
M-107
Feasibility of predicting regional lung exposure from systemic pharmacokinetic data of generic orally inhaled drug products (OIDPs) via population pharmacokinetic and non-compartmental approaches
Favorite
S-051
First-In-Human TBD11 dose range prediction through a multispecies minimal PBPK model
Favorite
S-080
Fluorescence timer-based analysis of latency-reversing agent effectiveness in HIV
Favorite
S-074
From Data to Parameters: FIVEDB as a Tool for Efficient QSP Model Calibration
Favorite
M-075
From hot to cold: Modeling radiocopper kinetics in Wilson’s Disease to simulate cold copper endpoints
Favorite
T-038
From in vitro to in vivo via Machine Learning: Predicting preclinical pharmacokinetics for small molecules in the data-scarce regime
Favorite
S-042
Full covariate model construction, usage, and reduction in population pharmacokinetics
Favorite
G
M-045
Ghqc: An R-based Open-Source Tool for Semi-Automated Quality Control on GitHub
Favorite
T-044
GitHub-based QC Review Workflow for Pharmacometrics Projects
Favorite
T-091
gQSPTwin: A MATLAB-Based Application for Automation and Standardization of the QSP Digital Twin Generation Workflow
Favorite
H
M-080
Harnessing Machine Learning and Real-World Data: Comparative Analysis of Cross-Sectional and Longitudinal Clustering in Patient Trajectories from Electronic Health Records
Favorite
M-015
Hybrid MBMA-QSP Model Predicts T Cell Engager Plus Cereblon E3 Ligase Modulatory Drugs Combination Outcomes As A Function Of Prior Therapies In Relapsed/refractory Multiple Myeloma
Favorite
I
M-089
Identifying an optimal dose range for clinical development of BT7480 using a fit-for-purpose quantitative system pharmacology (QSP) modeling
Favorite
S-108
Impact of Misspecified Residual Error Model for Heavy-Tailed Error Distribution on PK Model Parameter Estimates
Favorite
M-027
Implementation of Distributed Delay Differential Equations in RADAU5 and RADAR5
Favorite
S-027
Implementation of Efron Correction for Tied-time Records in Time-variant and Time-invariant Cox Proportional Hazard Model in NONMEM
Favorite
S-015
Improving Physical Activity Classification with Free-living Wrist Sensor Data: Diving into Unique Feature Groups
Favorite
T-034
In silico model of hypertrophic cardiomyopathy caused by MYBPC3 mutation predicted key drivers of cardiomyocyte morphology
Favorite
T-116
Inference of Pathological States from Skin Eruption Morphology for Drug Efficacy Evaluation and Personalized Treatment in Skin Disease
Favorite
S-061
Insights into Guide-Effector Antigen Interaction for Bispecific Antibody Design Using a Mechanistic Model
Favorite
M-019
In silico validation of MARIPOSA trial outcomes in EGFR‑mutated NSCLC using a QSP‑based disease model integrated with a newly implemented lazertinib drug model
Favorite
T-035
Integrating Age-Related Immune Differences to Enhance Vaccine Response Predictions of a Quantitative Systems Pharmacology (QSP) Model
Favorite
M-041
Integrating Machine Learning and Magnetic Resonance Imaging Radiomics for Trajectory Modeling in Duchenne Muscular Dystrophy: Explainable Artificial Intelligence to Inform Clinical Trial Design and Personalized Intervention
Favorite
M-007
Intravenous Immunoglobulin G (IVIG)-Monoclonal Antibody (mAb) Drug Interactions: Time for Model-Informed Clinical Guidance?
Favorite
M-059
Investigating the Role of Epithelial Barrier Function in Inflammatory Bowel Disease with Mechanistic Modeling
Favorite
S-085
Investigating the Role of Estradiol in Oxidative Stress in Health and Disease: A Mechanistic Model
Favorite
T-037
Investigating tissue distribution of curcumin using Physiologically-based pharmacokinetic (PBPK) approach
Favorite
J
T-099
Joint modeling of serum M-protein and PFS to predict response to isatuximab in combination with bortezomib/lenalidomide/dexamethasone in newly diagnosed multiple myeloma patients
Favorite
L
S-053
Leveraging historical clinical trial data using Model-Based Meta-Analysis (MBMA) to investigate the impact of prior biologic therapy on the efficacy of treatments in Psoriatic Arthritis
Favorite
S-081
Leveraging Kolmogorov–Arnold Networks to Discover Time-Dependent Drug Efficacy Function
Favorite
T-036
Leveraging PBPK Modeling for Bioavailability Enhancement: Insights from In Vitro Dissolution and Cocrystallization Studies
Favorite
M-042
Leveraging Real-World Data for Osteoarthritis Severity Score Modeling: An InSilicoTrials Platform Application
Favorite
M
M-040
Machine Learning and Chemical Language Model-Based QSAR Models for Predicting Plasma and Tissue Half-Lives of Drugs in Cattle Across Various Administration Routes
Favorite
M-040
Machine Learning and Chemical Language Model-Based QSAR Models for Predicting Plasma and Tissue Half-Lives of Drugs in Cattle Across Various Administration Routes
Favorite
S-039
Machine Learning and Mechanistic Modeling to Predict Intravenous Pharmacokinetic Profiles in Humans
Favorite
M-076
Machine learning approach links QSP virtual populations with key lesion types and clinical scoring in hidradenitis suppurativa
Favorite
M-051
Machine Learning Augmented Tumor Growth and Survival Models: Insights from Hepatocellular Carcinoma Data
Favorite
S-068
Machine learning for exploratory data analysis and model diagnosis in oncology
Favorite
S-093
Machine Learning-Integrated Physiology-Based Pharmacokinetic Modeling for Optimizing Nanoparticle Design
Favorite
T-067
Mathematical Modeling of Tumor Response to Fibroblast Activation Protein (FAP)-Targeted Radiopharmaceutical Therapy
Favorite
S-102
Mathematical Modeling to Optimize Receptor Occupancy Assay Development for Isatuximab
Favorite
S-037
Mechanism-based PBPK Modeling Reveals Nonlinear Brain Pharmacokinetics of Fluvoxamine: Roles of Active Influx and Brain Metabolism
Favorite
M-036
Mechanistic Insights by Combining Quantitative Systems Pharmacology (QSP) and Machine Learning: An Inflammatory Bowel Disease Case Study
Favorite
S-035
Mechanistic insights on diverse in vivo tumor efficacy outcomes for bispecific T-cell engagers using a quantitative systems pharmacology model
Favorite
M-064
Mechanistic Insights Uncover Novel Therapeutic Targets in Cardiac Hypertrophy
Favorite
T-075
Mechanistic Modeling and Unsupervised Learning Reveal Drivers of Inter-Individual Variability in COVID-19 Vaccine-Induced Immunity
Favorite
T-092
Mechanistic Modeling of Bispecific Antibody Combination Therapy to Optimize TumorKilling in Cancer Immunotherapy
Favorite
T-102
Methylprednisolone PK/PD in a Rat Model of Cytokine Release Syndrome
Favorite
S-109
Mixed Effects Modeling of Diurnal Cortisol Dysregulation in Long COVID
Favorite
S-057
mlxDesignEval: A novel R package for design evaluation based on MonolixSuite, and its comparison to popED and PFIM
Favorite
M-049
Model Platform to Predict Overall Survival for Patients with Relapsed and Refractory Multiple Myeloma
Favorite
T-068
Model selection for precision dosing: Comparison of Machine Learning and Evidence-plus-Expertise Algorithms
Favorite
S-082
Model-Based Approach to Support Nivolumab Subcutaneous Dose Selection in Pediatric Patients (12 to <18 Years) in Multiple Solid Tumor Indications
Favorite
M-086
Model-Based Evaluation of Lumasiran Plasma and Liver Pharmacokinetics in Non-Human Primates
Favorite
M-043
Model-based meta-analysis of objective response rate and overall survival in recurrent/metastatic head and neck squamous cell carcinoma
Favorite
M-066
Model-informed Assessment of the Impact of Relaxing the high-sensitivity C-reactive protein Inclusion Criteria on Patient Enrollment and Efficacy Signal in Rheumatoid Arthritis Clinical Trial Design
Favorite
T-043
Model-informed Clinical Trial Design for Autosomal Dominant Tubulointerstitial Kidney Disease: Integrating Disease Progression and Trial Simulation
Favorite
T-008
Model-informed dose priming strategy for T cell engagers: Leveraging early clinical data to mitigate CRS
Favorite
T-008
Model-informed dose priming strategy for T cell engagers: Leveraging early clinical data to mitigate CRS
Favorite
S-104
Model-Informed Dose Selection for mRNA-3927 in Participants with Propionic Acidemia (PA)
Favorite
S-104
Model-Informed Dose Selection for mRNA-3927 in Participants with Propionic Acidemia (PA)
Favorite
T-113
Model-informed Evidence Generation to Optimize Warfarin Dosing for Hepatic Impairment
Favorite
S-103
Model-Informed Oral Tacrolimus Dose Optimization for Adult Recipients of Allogeneic Hematopoietic Cell Transplantation Receiving Post-Transplant Cyclophosphamide
Favorite
S-045
Model-informed scheduling of drug combinations for optimal treatment of cancer: a case study of JDQ443 and TNO155 dose regimen optimization
Favorite
M-084
Modeling Blood Urea Nitrogen (urea) Dynamics to Estimate Dialysis Adequacy
Favorite
M-084
Modeling Blood Urea Nitrogen (urea) Dynamics to Estimate Dialysis Adequacy
Favorite
T-048
Modeling clinical trial design in infectious disease outbreaks considering differences in IC50 between in vitro and in vivo
Favorite
S-036
Modeling for prediction of CCR8 receptor occupancy in human tumor tissues after dosing of S-531011, a humanized anti-CCR8 monoclonal antibody
Favorite
T-058
Modeling Huntington’s disease progression utilizing the Huntington’s disease integrated staging system
Favorite
M-081
Modeling Interactions Between Respiratory Pathogens
Favorite
S-067
Moment closure for uncertainty propagation in QSP models
Favorite
T-049
Monte-Carlo simulations to assess isavuconazole probability of pharmacokinetic-pharmacodynamic target attainment (PTA) for Chinese pediatric patients with invasive aspergillosis (IA) or invasive mucormycosis (IM)
Favorite
T-017
Multi-Objective Optimization for Population Pharmacokinetic Model Selection: Evaluating Non-dominated Sorting Genetic Algorithm III Performance
Favorite
M-014
Multiple myeloma QSP model enables evaluation of iberdomide dosing schedules post-ASCT in NDMM patients for the EXCALIBER Maintenance study
Favorite
N
T-032
Navigating Challenges in Dose-Exposure-Response Analysis in the Presence of Confounding Associated with Titrated Drug Regimens
Favorite
S-043
Near Real-Time Apixaban Clinical Dose Decision-Making in Treating a Neonatal Venous Thromboembolism Population Using the InsightRX Nova™ Platform
Favorite
S-002
nlmixr2, rxode2 and Monolix: interchangeable models using monolix2rx and babelmixr2
Favorite
O
M-030
Observed and Simulated Pharmacokinetics and Pharmacodynamics of Nipocalimab in Adults with Sjögren’s Disease: Results from a Phase 2, Multicenter, Randomized, Placebo-controlled Study
Favorite
M-077
Ocular Pharmacokinetic/Pharmacodynamic Modeling of Drug Release from Single- and Bi-Layered Polymeric Microspheres for Retinal Conditions
Favorite
T-114
Open-Source Modeling of Anti-Tuberculosis Drug-Induced Cardiac Risks for Safe Dose Prediction
Favorite
M-004
Optimal Sampling Workflows with NMsim and NONMEM
Favorite
S-017
Optimal therapeutic combinations for Phase 3 UC trial design- recommendations from a QSP platform model
Favorite
T-001
Optimization of Ponsegromab PK/PD Assessments in Phase 3 Studies by Clinical Trial Simulation
Favorite
T-023
Optimizing Clinical Trial Design through In Silico Modeling, Virtual Populations, and Mathematical Optimization
Favorite
M-109
Optimizing Duchenne Muscular Dystrophy Clinical Trial Design by Modeling and Simulation: Identifying Characteristics of Magnetic Resonance Imaging Fat Fraction and Timed Function Test Measures and Their Longitudinal Association
Favorite
M-032
Optimizing Pediatric Doses for Weight-Based Dosing Regimens Under Constraints
Favorite
M-068
Optimizing QSP Modeling Workflows with CYTOCON DB: A Comprehensive Repository of In Vivo Cell and Cytokine Concentrations
Favorite
S-079
Osimertinib optimal dosing through population pharmacokinetics in virtual patients with NSCLC
Favorite
T-025
Overcoming Temporal and Quality Challenges in Dataset Creation for Pharmacometrics Analysis
Favorite
P
S-065
Performance Verification and Application of Endogenous Biomarker Coproporphyrin I in the Simcyp™ Simulator V23
Favorite
M-090
Pharmacoequivalence vs Bioequivalence: A role for MIDD analysis in bioequivalence studies
Favorite
T-074
Pharmacokinetic and Exposure-Response Modeling Support Body Surface Area-Based Dosing of Farletuzumab Ecteribulin in Patients with Solid Tumors
Favorite
T-095
Pharmacokinetic Modeling of Prophylactic Dose Rivaroxaban Transfer into Human Milk
Favorite
T-063
Pharmacokinetic-pharmacodynamic (PK-PD) modeling and simulation of a Novel, Directly Acting Antiviral, BDGR-251, in EEEV Infected Mice
Favorite
S-034
Pharmacometric analysis of pharmacokinetics, safety, and efficacy data of migoprotafib in combination with divarasib for KRAS G12C-positive non-small cell lung cancer.
Favorite
T-085
Pharmacometric Modeling of Clazakizumab in Patients Undergoing Maintenance Dialysis
Favorite
M-065
Pharmacometrics and Machine Learning-Based Modeling to Assess the Impact of Vaginal Microbiome on Tenofovir Exposures in the Female Genital Tract of African Women
Favorite
S-064
Physiologically Based Pharmacokinetic Modeling of Quizartinib to Assess Drug-Drug Interaction as an Inhibitor of Breast Cancer Resistance Protein
Favorite
M-088
PK/PD Analysis of the Primary Endpoint for Nipocalimab in Sjögren's Disease
Favorite
T-110
PK/PD Modeling of Dexamethasone in Heart and Lung Tissues in an Animal Model of Cytokine Release Syndrome
Favorite
T-086
PK/PD Modeling Suggests Tumor Heterogeneity Limits Preclinical to Clinical Translation of Enzalutamide in Prostate Cancer
Favorite
T-030
PK/PD/PD Models Enable Quantitative Insights into the Exposure-Efficacy Relationships of Tirzepatide for Treatment of Obstructive Sleep Apnea
Favorite
S-083
PKPD investigation of BI-S across blood-ocular barrier
Favorite
S-077
Population Pharmacokinetic & Exposure-Response Analysis After Subcutaneous Administration of Guselkumab in Pediatric Participants with Moderate to Severe Plaque Psoriasis
Favorite
S-105
POPULATION PHARMACOKINETIC (POPPK) MODELING OF IRINOTECAN AND SN38 IN PARTICIPANTS WITH METASTATIC COLORECTAL CANCER (MCRC) IN PHASE 2 AND 3 STUDIES: A SEQUENTIAL PARENT-METABOLITE MODEL
Favorite
S-020
Population Pharmacokinetic Analysis of Domvanalimab in Patients with Solid Tumors
Favorite
M-069
Population Pharmacokinetic Analysis of Dupilumab in Patients With Chronic Obstructive Pulmonary Disease
Favorite
M-033
Population Pharmacokinetic Analysis of Possible Drug-Drug Interactions between Mouse Double Minute 2 (MDM2) Inhibitor Navtemadlin and the Bruton's Tyrosine Kinase (BTK) Inhibitor Acalabrutinib in Patients with R/R CLL or R/R DLBCL
Favorite
M-103
Population Pharmacokinetic Analysis of QRL-201 in Plasma and CSF in Patients With Amyotrophic Lateral Sclerosis From A First-in-Human Phase 1 Multiple Ascending Dose Escalation Study
Favorite
S-113
Population pharmacokinetic analysis of sertraline in pregnant individuals
Favorite
S-113
Population pharmacokinetic analysis of sertraline in pregnant individuals
Favorite
M-094
Population Pharmacokinetic Analysis of Zimberelimab in Patients with Solid Tumors
Favorite
T-079
Population Pharmacokinetic Analysis to Characterize Pharmacokinetics of Sarilumab in Pediatric Participants with Polyarticular-Course Juvenile Idiopathic Arthritis
Favorite
M-070
Population pharmacokinetic and exposure-response analysis of high-dose methotrexate-associated mucositis in infant patients with acute lymphoblastic leukemia
Favorite
M-070
Population pharmacokinetic and exposure-response analysis of high-dose methotrexate-associated mucositis in infant patients with acute lymphoblastic leukemia
Favorite
T-072
Population pharmacokinetic model-informed dose selection for exogenous hemopexin (CSL889) in patients with sickle cell disease
Favorite
S-084
Population pharmacokinetic modeling of anti-B7H4 antibody-drug conjugate (SGN-B7H4V) in patients with advanced solid tumors from phase 1 study
Favorite
M-010
Population Pharmacokinetic Modeling of Encorafenib and LHY746 In Participants with Solid Tumors in Phase 2 Studies: A Sequential Parent-Metabolite Model
Favorite
M-002
Population Pharmacokinetic Modeling of MEDI7352, a Bispecific Fusion Protein for Dual Targeting of NGF and TNFα, in Patients with Painful Diabetic Neuropathy and Painful Osteoarthritis of the Knee
Favorite
S-098
Population Pharmacokinetic Modeling of Rezpegaldesleukin after Subcutaneous Dosing to Account for Variability Across Multiple Patient Populations with Autoimmune Diseases
Favorite
S-059
Population Pharmacokinetic, Exposure-Response, and Time-To-Event Analyses of Probenecid in Symptomatic, Non-Hospitalized Patients with COVID-19
Favorite
T-080
Population Pharmacokinetic/Pharmacodynamic Modeling and Analysis of Tetrahydrobiopterin and Blood Phenylalanine Response in Adult and Pediatric Patients with Phenylketonuria During Sepiapterin Treatment
Favorite
T-071
Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Lorlatinib-treated Patients with Non-small Cell Lung Cancer
Favorite
S-006
Population Pharmacokinetics and Exposure-Response Analysis for TAR-200, an Intravesical Drug Delivery System for Bladder Cancer Treatment
Favorite
M-095
Population Pharmacokinetics and Exposure-response Analysis of Cemsidomide in Patients with Relapsed/Refractory Multiple Myeloma and Non-Hodgkin’s Lymphoma
Favorite
S-047
Population Pharmacokinetics and Exposure-Response Analysis of Nivolumab in Combination with Ipilimumab in Participants with First-Line Unresectable or Advanced Hepatocellular Carcinoma to Support Benefit-Risk Assessment
Favorite
M-054
Population pharmacokinetics and exposure-safety analysis of SGN-STNV (PF-08046055) in patients with locally advanced and/or metastatic solid tumors: Phase-1a/b study
Favorite
M-072
Population Pharmacokinetics and Pharmacodynamic Analysis of MT-4561, a Novel Bromodomain-containing Protein 4 (BRD4) Protein Degrader
Favorite
M-012
Population pharmacokinetics and pharmacodynamics analysis of PF-07328948, a branched-chain ketoacid dehydrogenase kinase inhibitor, in healthy participants
Favorite
S-024
Population Pharmacokinetics of AMG 193 and its Impact on SDMA Inhibition in Patients with Advanced MTAP-deleted Solid Tumors
Favorite
T-094
Population Pharmacokinetics of Brensocatib in Adult and Adolescent Patients with Non-Cystic Fibrosis Bronchiectasis (BE)
Favorite
T-084
Population Pharmacokinetics of Deutetrabenazine in Asian Individuals
Favorite
T-104
Population Pharmacokinetics of Dexmedetomidine in Neonates with Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic Hypothermia: Insights from a Prospective Real-World Study
Favorite
S-055
Population Pharmacokinetics of Elranatamab in Chinese Patients with Relapsed or Refractory Multiple Myeloma using PRIOR Approach
Favorite
T-111
Population Pharmacokinetics of Levocetirizine in Children with Uncontrolled Allergic Asthma: An Ongoing Study
Favorite
T-046
Population Pharmacokinetics of Subcutaneous Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Favorite
T-082
Population PK and PK/PD Modeling of Apitegromab in Spinal Muscular Atrophy Patients
Favorite
S-003
Population PK Modeling of Ziftomenib and its Metabolites in Healthy Subjects and in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Favorite
S-115
Population PK/PD Modeling to Optimize Dosing of BIIB107, an Anti-Alpha-4 Integrin Monoclonal Antibody
Favorite
S-008
Population PK-RO-IgG Modeling of Nipocalimab in Patients with Sjögren's Disease
Favorite
T-033
Practical PK/PD Modeling of Lymphocytes and CD4+ T Cells in HIV Patients Treated with the Nucleoside Reverse Transcriptase Translocation Inhibitor (NRTTI) Islatravir
Favorite
S-117
Predicting Clinical Mosunetuzumab CD20 Receptor Occupancy using a Minimal Physiologically–Based Pharmacokinetic (mPBPK) Modeling Approach
Favorite
M-035
Predicting Improved Weaning Strategies for Mechanical Ventilation with a Physiologically-Based Mechanistic Model
Favorite
T-039
Predicting Tumor Growth Dynamics and Overall Survival with Deep Learning Model
Favorite
M-047
Prediction of human pharmacokinetic profiles of Glyph(TM) platform prodrugs using animal and human data via a semi-mechanistic pharmacokinetic model
Favorite
M-001
Prediction of Percent Free Nerve Growth Factor Suppression following Administration of MEDI7352, a Bispecific Fusion Protein for Dual Targeting of NGF and TNFα, in Patients with Painful Diabetic Neuropathy and Osteoarthritis
Favorite
T-055
Prospective Physiologically Based Pharmacokinetic Modeling Predictions of First-in-Patient Study PK: Examples and Application
Favorite
S-013
Proteosis-Targeting Chimera Efficacy Prediction Using a Deep-Learning–QSP Model
Favorite
Q
S-086
QSP I-O & ADCs: Integration of an antibody-drug conjugates mechanistic model into an immuno‐oncology quantitative systems pharmacology platform
Favorite
M-013
QSP Model of Nivolumab in Combination with Bispecific T Cell Engagers predicts Enhanced Anti-Tumor Immunity
Favorite
T-066
QSP Model of RSV Viral Dynamics in Healthy Adult and Pediatric Patient Populations
Favorite
T-053
QSP Modeling of Potassium Regulation in Rare and Complex Cardiorenal Disorders
Favorite
M-092
QSP modeling to inform key clinical dosing regimen decisions for an engineered IL15 cytokine Efbalropendekin alfa in patients with solid tumors
Favorite
S-056
Quantitative Assessment of Glecaprevir and Pibrentasvir Exposures in Adults with Chronic or Acute HCV Infection: A Comprehensive Analysis of Phase 2 and 3 Studies Utilizing Subject Matching and Population PK Simulations
Favorite
T-115
Quantitative investigation of ATP switch concept of STA551 by combined in vivo tissue distribution study and physiologically-based pharmacokinetic modeling
Favorite
M-063
Quantitative Model of the Ocular Immune Response to Seasonal Allergic Conjunctivitis
Favorite
S-050
Quantitative systems modeling of inflammation and coagulation abnormalities induced by pathogen infection
Favorite
M-011
Quantitative Systems Pharmacology (QSP) Modeling of efficacy and nausea of GLP-1 mono and dual (GLP-1/GIP) receptor agonists (RA) to support weight management and glycemic control in obese patients
Favorite
M-057
Quantitative Systems Pharmacology Modeling to Support First-in-Human Dose Selection for a CD3 Bispecific Antibody in B-Cell Lymphoma and Renal Cell Carcinoma
Favorite
R
T-010
Rat as a Predictive Model for Human Clearance and Bioavailability of Monoclonal Antibodies
Favorite
M-055
Real World Data Based Evaluation of a Novel TMDD Approximation Model
Favorite
S-096
Real-world Data Driven Pediatric Dose Extrapolation: A Novel Model-informed Drug Development Approach
Favorite
M-050
Real-world Performance Assessment and Model Re-evaluation in Children and Adults
Favorite
T-016
Reducing Animal Use in Toxicological Research through Open-Source Individualized (PB)PK/QST Modeling: A Case Study with Phenobarbital in Dogs
Favorite
M-110
Re-evaluation of Fixed dosing versus Body Size-Based Dosing Approaches for Large Molecule Therapeutics in Adults
Favorite
M-067
reportifyr: an R-based Open-Source Tool for Automated Reporting
Favorite
S-111
Re-Purposing Bispecific Antibodies in Autoimmune Diseases: MIDD Based Dose Optimization Strategies
Favorite
T-054
Retrospective analysis of systemic and dermal PK of several anti-inflammatory topicals using SimCYP MechDermA model explains the observed clinical efficacy of successful and failed drugs
Favorite
T-108
Right Dose, Wrong Patient? Clinical Perspectives on Atomoxetine Nonresponse in ADHD
Favorite
S-066
Right-Sizing Models: A Model Reduction Approach Applied to Models of the Treatment of Solid Tumors by Protein Degraders
Favorite
M-006
Risk Based Validation Strategy for Pharmacometric Analysis Ready Dataset to improve efficiency and effectiveness
Favorite
S
T-026
Semi-Automated Quality Check Process for NONMEM Dataset Using R Markdown
Favorite
S-107
Semi-Mechanistic Model for LNP-mediated In-vivo CAR T-Cell Engineering and B-Cell Depletion in Primates
Favorite
T-042
SimKid: An R package for Simulation of Virtual Pediatric Subjects
Favorite
T-069
Simplifying the Communication of Covariate Effects from Pharmacometric Models - The Role of Unconditional Covariate Effects
Favorite
S-110
Simulating Relative Infant Hydroxyurea Dose Through Breastfeeding Using a Semi-Mechanistic Population PK Model
Favorite
T-003
Simultaneous Modeling of Ponsegromab PK, PD and Clinical Response in Patients with Cancer Cachexia
Favorite
M-096
Simultaneous PASI Exposure Response Analysis of Ustekinumab in Subjects with Psoriasis and Psoriatic Arthritis
Favorite
S-112
Sparse Sampling Strategies for Monoclonal Antibody Pharmacokinetics: Evaluating Estimation Methods for Reliable Clearance Assessment
Favorite
M-102
Strategic application of PK modeling in 505(b)(2) development for a new pediatric formulation
Favorite
S-029
Supporting ICH M15 Principles Through a Collaborative Platform for Good Simulation Practices
Favorite
S-014
Survival Modeling of Dementia Risk Using Metabolic Syndrome-Related Genetic Variants
Favorite
T
S-033
The Dose and Dosing Schedule Selection for an Investigational Immuno-Oncology Drug Based on a Pharmacokinetics and Pharmacodynamic Model of Tolerance
Favorite
S-040
Time-to-event analysis of iron homeostasis to inform survival in cancer patients
Favorite
M-056
Time-to-event exposure-response based clinical utility index framework to facilitate optimal dose selection
Favorite
M-023
Towards uncertainty assessment-based acceptability thresholds for model validation?
Favorite
M-005
Transforming Pharmacometric Processes to deliver medicines to patients: Balancing Speed, Quality, and Innovation
Favorite
M-058
Transforming the Development of Targeted Protein Degraders: The Translational Power of PK/PD Modeling beyond the Human Dose Projection
Favorite
M-034
Translating PROTACs: Relating in vitro Potency to Protein Degradation Kinetics
Favorite
M-009
Translation of a Preclinical Tumor Growth Inhibition Model to a Clinical Setting: Two Approaches to Incorporate Resistance in a Tumor Dynamics Model
Favorite
T-006
Translational two-pore PBPK model to characterize whole-body disposition of different-size oligonucleotide therapeutics
Favorite
U
S-100
Understanding How Low Calorie Sweeteners Pass from Mother to Infants Through Breastmilk – Insights from Population Pharmacokinetic Modeling
Favorite
S-100
Understanding How Low Calorie Sweeteners Pass from Mother to Infants Through Breastmilk – Insights from Population Pharmacokinetic Modeling
Favorite
S-049
Understanding PK/PD relationship of CD19 CAR-T (BMS-986353) in Systemic Lupus Erythematosus (SLE) using a mechanistic quantitative pharmacology framework
Favorite
S-007
Understanding the Utilization of SDTM and ADaM Datasets in Pharmacometric Programming
Favorite
S-052
Update on Current Status of PBPK Modeling Application in Hepatic Impairment Populations: Recent Successes & Knowledge Gaps
Favorite
T-107
Use of Emtricitabine-Triphosphate Concentrations in Dried Blood Spots to Evaluate Pre-Exposure Prophylaxis (PrEP) Adherence
Favorite
S-089
Use of population time-activity curve modeling and simulation to support the reduced tumor dosimetry collection timepoints in radioligand therapy (RLT) clinical trials
Favorite
S-091
Use of the Animal Rule to Develop JST-010 for Pre-Exposure Prophylaxis Against Infection by Yersinia pestis
Favorite
M-108
Using Modeling and Simulation to Assess the Impact of the Pharmacokinetics and Biodistribution on the Absorbed and Biologically Effective Dose for Radioligand Therapies
Favorite
T-022
Using Population Pharmacokinetics and Simulation to Develop SAT-3247 for the Treatment of Duchenne Muscular Dystrophy in Pediatric Patients
Favorite
S-011
Using translational in vitro-in vivo modeling to improve inhaled drug repurposing outcomes for COVID-19
Favorite
T-021
Utilizing Generative Deep Learning and Bayesian Neural Network for Pharmacometrics Covariate Analysis
Favorite
M-062
Utilizing MechDermA model for early feasibility analysis in topical drug discovery
Favorite
V
S-016
Verification of an algorithm for detection of pronation-supination movements in Parkinson’s disease.
Favorite
T-076
Virtual clinical trial simulations across treatment lines using a QSP model of CDK inhibitors in breast cancer patients
Favorite
Z
T-031
Zelenectide Pevedotin, a Bicycle Drug Conjugate (BDC®), Does Not Present Clinically Meaningful QT Prolongation Risk as Demonstrated by A Concentration-QTc (C-QTc) Analysis
Favorite
